Sindrom Ekstrapiramidal (EPS)

01Pathophysiology

The extrapyramidal system refers to the motor pathways that modulate voluntary movement outside the corticospinal (pyramidal) tract. The key structure is the basal ganglia, which includes the caudate nucleus, putamen (together forming the striatum), globus pallidus, subthalamic nucleus, and substantia nigra. Movement fluidity depends on a carefully maintained balance between dopaminergic (inhibitory) and cholinergic (excitatory) neurotransmission within the striatum.

Antipsychotic medications, particularly first-generation agents, exert their therapeutic effect by blocking dopamine D2 receptors in the mesolimbic pathway. However, D2 blockade is not pathway-selective. When the same blockade occurs in the nigrostriatal pathway, the result is a relative dopamine deficiency in the striatum. This shifts the balance toward unopposed cholinergic activity, producing a state that functionally resembles the pathology seen in Parkinson disease (where dopaminergic neurons in the substantia nigra pars compacta degenerate).

This mechanism explains why the clinical manifestations of EPS mirror parkinsonian features: rigidity, tremor, bradykinesia, and abnormal involuntary movements all result from disrupted basal ganglia output to the thalamus and motor cortex. The degree of D2 receptor occupancy correlates with EPS risk, which is why high-potency typical antipsychotics (haloperidol, fluphenazine) carry the highest risk, while low-potency typicals (chlorpromazine) and atypical antipsychotics (quetiapine, clozapine) have lower EPS liability due to their additional serotonin 5-HT2A antagonism and relatively lower D2 binding affinity.

There is a critical temporal relationship between drug exposure and the type of EPS that emerges. This timeline is one of the most heavily tested concepts:

• Hours to days after initiation: Acute dystonia

• Days to weeks: Akathisia

• Weeks to months: Drug-induced parkinsonism

• Months to years (typically after >3 months of cumulative exposure): Tardive dyskinesia

Understanding this timeline is essential because the vignette will often anchor the diagnosis to "how long ago the medication was started."

Neuroleptic malignant syndrome (NMS) is a separate, idiosyncratic, life-threatening reaction. While also caused by D2 blockade, NMS involves a more profound disruption of central thermoregulation in the hypothalamus and a generalized sympathetic hyperactivation, producing hyperthermia, autonomic instability, rigidity, and rhabdomyolysis. Unlike the dose-dependent EPS subtypes, NMS can occur at any dose and any time point, though it most commonly appears within the first two weeks of treatment or after dose escalation.

02Classification and Clinical Manifestation

Tardive dyskinesia is the only EPS subtype that worsens when the offending drug is discontinued abruptly and may transiently improve when the dose is increased (because increased D2 blockade temporarily suppresses the upregulated receptors).

03Diagnostic Workup

All subtypes of EPS are fundamentally clinical diagnoses. There is no single confirmatory laboratory test or imaging study that establishes EPS. The diagnosis rests on three pillars: (1) exposure to a dopamine-blocking agent, (2) the appropriate temporal relationship between drug initiation and symptom onset, and (3) the characteristic movement abnormality on examination.

For acute dystonia, the clinical picture is usually unmistakable. A young patient recently started on haloperidol who develops torticollis or oculogyric crisis within hours needs no workup. The diagnosis is confirmed therapeutically: if IV diphenhydramine or benztropine resolves the dystonia within minutes, that response is effectively diagnostic.

Akathisia is more subtle and is frequently misdiagnosed as worsening psychosis or anxiety, which leads to the dangerous trap of increasing the antipsychotic dose (the exact wrong intervention). The distinguishing feature is the motor component: the patient is not merely anxious but physically unable to remain still, with observable restless leg movements, shifting, and pacing that the patient recognizes as involuntary.

Drug-induced parkinsonism can be difficult to distinguish from idiopathic Parkinson disease. The critical discriminators are (1) the temporal onset following antipsychotic use, (2) bilateral and symmetric symptoms (idiopathic Parkinson disease typically starts unilaterally), and (3) the absence of progression after the drug is discontinued. If diagnostic doubt persists, a DaTscan can differentiate: normal dopamine transporter uptake in drug-induced parkinsonism versus reduced uptake in true Parkinson disease.

For tardive dyskinesia, the Abnormal Involuntary Movement Scale (AIMS) is the standard assessment tool. The AIMS should be performed at baseline before starting an antipsychotic and at regular intervals (every 6 months for typical antipsychotics, every 12 months for atypical agents). Diagnosis requires exclusion of other causes of chorea, including Huntington disease (genetic testing, family history), Wilson disease (ceruloplasmin, slit-lamp exam for Kayser-Fleischer rings), and Sydenham chorea (anti-streptolysin O titer, history of rheumatic fever).

NMS is a medical emergency that demands immediate laboratory evaluation. The hallmark finding is a dramatically elevated CK reflecting skeletal muscle breakdown from sustained rigidity. Additional laboratory findings include leukocytosis, elevated hepatic transaminases, hyperkalemia, metabolic acidosis, and myoglobinuria. These labs are not diagnostic in isolation but are critical for monitoring complications, particularly rhabdomyolysis-induced acute kidney injury, which is the leading cause of death in NMS.

04Management & Treatment

Acute Dystonia is a medical urgency, not because it is usually fatal, but because it is terrifying for the patient and can become life-threatening if laryngospasm occurs, compromising the airway. The treatment is straightforward: administer an anticholinergic agent immediately. IV diphenhydramine works within 5 minutes. After the acute episode resolves, oral benztropine should be continued for at least 48 to 72 hours because the antipsychotic's half-life typically outlasts the single anticholinergic dose, and dystonia will recur if not covered. The clinician must then decide whether to continue the antipsychotic with prophylactic anticholinergic coverage, reduce the dose, or switch to a lower-risk agent.

Akathisia is the only EPS subtype where anticholinergics are not first-line. The best initial treatment is propranolol, a lipophilic beta-blocker that crosses the blood-brain barrier. If beta-blockers are contraindicated (asthma, severe bradycardia), benzodiazepines (lorazepam 0.5 to 1 mg two to three times daily) are an alternative. The most important management step, however, is to reduce the antipsychotic dose or switch to a lower-risk agent. Increasing the antipsychotic dose because the patient appears "agitated" is a dangerous and commonly tested mistake.

Drug-induced parkinsonism is managed similarly to acute dystonia in that anticholinergics (benztropine, trihexyphenidyl) are effective. However, the preferred approach is to switch to an atypical antipsychotic. Importantly, levodopa is generally not used for drug-induced parkinsonism because it would counteract the therapeutic D2 blockade needed for psychosis control. Anticholinergics should not be used indefinitely; attempt a taper after 2 to 3 months.

Tardive dyskinesia requires a fundamentally different approach because it is caused by receptor upregulation, not acute blockade. Anticholinergics will worsen tardive dyskinesia (this is a classic trap). The FDA-approved agents are vesicular monoamine transporter 2 (VMAT2) inhibitors: valbenazine and deutetrabenazine. These drugs reduce dopamine release from presynaptic vesicles, decreasing the overstimulation of upregulated postsynaptic receptors. The offending antipsychotic should be tapered if psychiatrically feasible, but abrupt discontinuation can paradoxically unmask or worsen movements ("withdrawal dyskinesia").

NMS management is an emergency protocol. The first and most critical step is immediate discontinuation of the offending agent. All subsequent management is supportive and pharmacologic. Dantrolene acts directly on skeletal muscle by inhibiting calcium release from the sarcoplasmic reticulum, reducing rigidity and heat generation. Bromocriptine is a dopamine agonist that restores dopaminergic tone centrally. Aggressive IV hydration with normal saline is essential to prevent rhabdomyolysis-driven acute kidney injury, and alkalinization of the urine may be considered to prevent myoglobin cast formation. External cooling blankets address hyperthermia. Benzodiazepines can be used adjunctively for agitation. After NMS resolves, if an antipsychotic must be restarted, a waiting period of at least 2 weeks is recommended, and the rechallenge should use a low-potency or atypical agent (quetiapine or clozapine carry the lowest NMS risk) at the lowest effective dose with very gradual titration.

05Differential Diagnosis & Distractors

06Traps & High-Yield Pearls

The most commonly tested trap with extrapyramidal syndromes is misidentifying akathisia as worsening psychosis. The vignette will describe a patient on an antipsychotic who appears agitated, restless, and unable to sit still. The wrong answer is to increase the antipsychotic dose (which worsens akathisia). The correct answer is to recognize the motor restlessness, reduce the dose, and start propranolol. Students who do not distinguish subjective psychotic agitation from the motor-driven restlessness of akathisia will consistently choose the wrong management.

The second major trap involves tardive dyskinesia and anticholinergics. Because anticholinergics treat most other EPS subtypes effectively, students instinctively reach for benztropine when they see involuntary movements in a patient on an antipsychotic. However, tardive dyskinesia is the exception: anticholinergics make it worse. The correct answer for tardive dyskinesia is a VMAT2 inhibitor (valbenazine or deutetrabenazine). Recognizing the timeline (months to years of exposure) and the characteristic orofacial distribution is the key to avoiding this error.

The third trap is confusing NMS with serotonin syndrome. Both involve hyperthermia and altered mental status after a medication. The discriminators that the exam relies on are neuromuscular findings: NMS produces lead-pipe rigidity with bradyreflexia, while serotonin syndrome produces clonus and hyperreflexia. Additionally, serotonin syndrome includes gastrointestinal symptoms (diarrhea) that NMS does not, and onset is much more rapid (within hours).

Finally, students must internalize the temporal framework of EPS. Acute dystonia within hours, akathisia within days, parkinsonism within weeks, and tardive dyskinesia after months. When a vignette states "a patient started on haloperidol three days ago now presents with...", the timeline itself narrows the differential significantly. The core competency being tested is the ability to connect the type of movement disorder to the duration of antipsychotic exposure and to select the subtype-appropriate treatment without defaulting to a one-size-fits-all anticholinergic approach.